Skip to content

NeoGenomics NEO Reportable Segment — NET LOSS

Similar metrics at other companies

Ouster logo
OUSTReportable Segment — Net loss
-$17.47M+20.7%
Supernus Pharmaceuticals logo
SUPNReportable Segment — Net loss
-$2.29M+80.6%
Travere Therapeutics, Inc. logo
TVTXReportable Segment — Net loss
-$37.1M+10.0%
Hyliion logo
HYLNReportable Segment — Net loss
-$11.7M+32.4%
Sonida Senior Living logo
SNDAReportable Segment — Net loss
-$41.45M-218%
Vir Biotechnology, Inc. logo
VIRReportable Segment — Net loss
-$125.7M-3.9%

Other financials

Income statement

See full
Revenue$186.7M+11.1%
Gross profit$80.9M+10.4%
Operating income-$18.2M+34.4%
Net income-$17.1M+34.0%
EPS (diluted)-$0.13+35.0%

Balance sheet

See full
Cash & equivalents$146.1M-57.8%
Total debt$66.3M+5.3%
Total equity$828.8M-6.7%
Total assets$1.3B-15.9%

Cash flow

See full
Operating cash flow-$8.1M+67.9%
CapEx$5.0M+11.1%
Free cash flow-$13.1M+56.0%

Valuation

See full
Market cap$1.68B+86.5%
Enterprise value$1.6B+159%
P/S2.3×+0.9×

Profitability

See full
Gross margin43.2%-1.1pp
Operating margin-14.2%+1.1pp
Net margin-13.3%+2.4pp
FCF margin-4.9%

Returns & leverage

See full
Return on equity-11.6%+6.2pp
Debt / equity0.1×0.0×
Current ratio4.4×+2.4×

Where this comes from

Reported directly by NeoGenomics in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: NeoGenomics’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about NeoGenomics's reportable segment — net loss.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NeoGenomics's reportable segment — NET LOSS?
NeoGenomics (NEO) reported reportable segment — NET LOSS of -$17.11M in Q1 2026.
How has NeoGenomics's reportable segment — NET LOSS changed year-over-year?
NeoGenomics's reportable segment — NET LOSS increased by 34.0% year-over-year, from -$25.92M to -$17.11M.
What is the long-term trend for NeoGenomics's reportable segment — NET LOSS?
Over 3 years (2022 to 2025), NeoGenomics's reportable segment — NET LOSS has grown at a -9.2% compound annual growth rate (CAGR), from -$144.25M to -$108.03M.
What does reportable segment — NET LOSS mean?
This is the final bottom-line financial result for the reportable segment after all operating expenses, interest, taxes, and non-operating items have been deducted. A net loss indicates that the segment's total costs exceeded its revenues for the reporting period.